Enstilar

Enstilar is a prescription‑only topical foam that combines betamethasone dipropionate 0.05 % w/w and calcipotriol monohydrate 0.005 % w/w. The product belongs to the corticosteroid‑vitamin D analog class and is marketed in the European Union for plaque and scalp psoriasis. It is applied once daily to the skin, in the affected areas, forming a fine, non‑greasy foam that reduces inflammation and normalizes keratinocyte growth and improves comfort.

Enstilar is indicated for the topical treatment of specific psoriasis manifestations.

- Plaque psoriasis affecting the trunk, limbs, or other body sites, particularly when lesions are thin to moderately thick. - Scalp psoriasis, providing coverage of hair‑bearing areas without leaving a heavy residue. - Adjunctive use with other prescribed topical treatments, such as moisturizers or keratolytics, when a combined approach is clinically appropriate. - Short‑term maintenance after successful clearance to help prevent recurrence in previously affected areas.

Side‑effects reported with Enstilar are generally mild, but serious reactions can occur.

Common: - Mild skin irritation or burning at the application site. - Pruritus (itching). - Dryness or flaking of the treated skin. - Transient erythema.

Serious: - Signs of skin atrophy such as thinning or bruising. - Development of secondary bacterial, fungal, or viral infections. - Allergic contact dermatitis. - Systemic corticosteroid effects (e.g., adrenal suppression) with extensive use.

Before using Enstilar, consider the following precautions to ensure safe and effective therapy.

- Avoid application to healthy skin, open wounds, or infected areas. - Do not use under occlusive dressings unless directed by a healthcare professional. - Limit treatment duration as advised; prolonged use may increase risk of skin atrophy. - Use caution in patients with a history of hypersensitivity to corticosteroids or vitamin D analogs. - Not recommended for use on the face, intertriginous zones, or mucous membranes unless specifically prescribed. - Pregnant or breastfeeding women should consult a physician, as safety data are limited.

Enstilar may interact with certain topical or systemic agents; awareness helps prevent reduced efficacy or increased toxicity.

Avoid: - Concurrent use with other potent topical corticosteroids on the same area, which can amplify systemic absorption. - Application together with topical calcineurin inhibitors, as combined immunosuppression may increase infection risk.

Use with caution: - Systemic vitamin D analogs or calcium supplements, which could raise serum calcium levels. - Antifungal or antibacterial creams applied to the same site, potentially altering drug absorption. - Phototherapy (UVB) performed on treated skin, as corticosteroids may reduce phototherapeutic response.